Drug intelligence / Profile preview

124I-18B10

Development stage
Unknown
Lead developer
Peking University Cancer Hospital & Institute
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration
Intravenous
01

Overview

124I-18B10 is an investigational **radiolabeled humanized monoclonal antibody** PET imaging agent designed for gastrointestinal tumors that overexpress Claudin 18.2. It consists of the humanized anti-CLDN18.2 antibody 18B10 labeled with iodine-124, enabling noninvasive positron emission tomography visualization of CLDN18.2-positive lesions. The agent has been studied in a phase 0 setting as a molecular imaging biomarker to identify patients who may benefit from CLDN18.2-targeted therapies and to support efficacy evaluation; thyroid blockade with iodine is used during imaging to reduce physiologic thyroid uptake of free radioiodine.

Other names
iodine-124 labeled 18B10iodine124 labeled 18B10iodine 124 labeled 18B10124I-labeled 18B10124I radiolabeled humanized anti-CLDN18.2 monoclonal antibody 18B10
02

Targets

Claudin 18.2

Beyond the preview

Go deeper on 124I-18B10.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 124I-18B10.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call